{
  "docId": "019de076-e431-717d-85d5-60fbb8c86744",
  "docSlug": "9614dd2dbfdf83d72e770ebfe5753af3",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 42,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a 'ribbon' or 'banner' layout on the right to highlight key product attributes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e431-717d-85d5-60fbb8c86744/39",
  "deckHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744",
  "deckJsonHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json",
  "deckAnchorHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.36,
        "x": 0.6,
        "y": 0.14
      },
      "kind": "list",
      "text": "Mechanism of Action: HER2-selective tyrosine kinase inhibitor. Stage of Development: IND-enabling studies; Phase 1 initiation planned in 2024. Initial Development Indication: HER2-positive NSCLC.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a91f73fc-624f-4295-a461-936138e09b65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.36,
        "x": 0.6,
        "y": 0.42
      },
      "kind": "list",
      "text": "Target Product Profile: Active against HER2 and HER2ex20; EGFR sparing; Brain penetrant.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9f47c1e-0dfb-49d9-a819-77ea6071e084",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.53,
        "x": 0.08,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "A brain-penetrant, HER2-selective inhibitor with activity against HER2 mutations and the potential to minimize EGFR-related adverse events",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9f69533-32de-4ea0-b73d-0ba4b3323393",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.14,
        "x": 0.715,
        "y": 0.06
      },
      "kind": "title",
      "text": "AT A GLANCE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32ccfbe2-387f-41b9-b93b-52b2978fa7e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.42,
        "x": 0.08,
        "y": 0.46
      },
      "kind": "title",
      "text": "NVL-330 for HER2+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9868432-d523-4f39-ab40-4627c8f17fbb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}